The North America human microbiome market is expected to reach US$ 446.39 Mn in 2025 from US$ 113.88 in 2017. The market is estimated to grow with a CAGR of 21.5% from 2018-2025. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies and growing technological advancements in human microbiome and next-generation sequencing. Whereas, strict government guidelines and lack of knowledge and detailed examination is likely to have a negative impact on the growth of the market in the coming years.

Humans are never alone as they coexist with the diverse microbial species that live within and upon humans. From recent studies it has been very clear that this microbial community is essentially another organ of the body that plays a crucial role in human physiology and disease. Several basic and translational research efforts have been initiated to focus on deciphering mechanisms of microbiome function and how it benefits the human health. Many human medical conditions (like inflammatory bowel diseases and obesity) have been closely associated with or are thought to be influenced by (asthma and diabetes) the composition of the gut microbial community. Many efforts are taken to alter the gut microbiome to eradicate several diseases. Probiotics, prebiotics dietary supplements and foods that contain live microbes have been studied thoroughly to assess their effects on human health.
The Human Microbiome Project of the National Institutes of Health in the United States and related international efforts are defining the varieties of a normal microbiome, studying how changes in the microbiota relate to disease. Large governmental research initiatives including the Human Microbiome Project in the U.S. have accelerated research on the human microbiome.
Also, many companies are designing and developing many microbiome therapies. For instance, Rebiotix Inc. has developed Microbiota Restoration Therapy (MRT) drug platform which is the drug platform for delivering healthy, live, human-derived microbes into a sick patient's intestinal tract to treat disease. Thus, the increasing focus on human microbiome therapies is the prime factor driving the growth of human microbiome market in the coming years.


US is anticipated to lead the adoptions of Human microbiome across the North American region through the forecast period. The application of the human microbiome are beneficial for various treatment areas such as cancer, Inflammatory Bowel Disease (IBD), diabetes, autoimmune diseases and more. To be specific with the applications of the human microbiome, it plays important role in the developments in wide range of diseases and disorders which includes cardiovascular disease, cancer, autoimmune, neurological disorders and more. Therefore, various programs are being organized in the country to grow the awareness of probiotics and prebiotics in order to enhance the human microbiome.
For instance, in February 2018, the 3rd Annual North America Microbiome Congress was held in San Diego, by Kisaco Research that focused on 5 microbiome niches such as the gut, lung, oral, skin and vaginal and provided latest insights on microbiome research, clinical trials and collaborative partnerships.
Thus, owing to the above mentioned factors the market for the human microbiome is likely to grow with a significant growth rate in the coming forecast years.

Exhibit: Mexico Human microbiome Market Revenue and Forecasts to 2027 (US$ Bn)



NORTH AMERICA HUMAN MICROBIOME- MARKET SEGMENTATION
By Product
- Probiotics
- Foods
- Prebiotics
- Medical Foods
- Diagnostic Device
- Drugs
- Supplements
NORTH AMERICA HUMAN MICROBIOME- MARKET SEGMENTATION
By Disease
- Obesity
- Diabetes
- Autoimmune Disorders
- Cancer
- Mental Disorders
- Others
NORTH AMERICA HUMAN MICROBIOME- MARKET SEGMENTATION
By Application
- Therapeutics
- Diagnostics

By Country
- U.S.
- Canada
- Mexico

Companies Mentioned
- Enterome
- MicroBiome Therapeutics, LLC
- Rebiotix Inc.
- Yakult Honsha Co., Ltd.
- Osel Inc.
- Vedanta Biosciences, Inc.
- Metabiomics Corporate
- Synthetic Biologics, Inc.
- DuPont
- BiomX Ltd.